ALLO Dividend: Allogene Therapeutics Inc Yield Insights

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	0	0	38	0
Revenue Growth (YoY)	--	--	--	-100%	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	58	65	71	79	74	65
Research & Development	166	192	242	256	220	192
Operating Expenses	225	257	314	335	294	258
Other Non Operating Income (Expenses)	0	--	-17	-1	-2	-1
Pretax Income	-211	-257	-327	-332	-257	-250
Income Tax Expense	--	0	--	--	0	0
Net Income	-212	-257	-327	-332	-257	-250
Net Income Growth	-60%	-21%	-2%	28.99%	3%	36%
Shares Outstanding (Diluted)	222.03	194.81	156.93	143.15	135.82	120.37
Shares Change (YoY)	6%	24%	10%	5%	13%	19%
EPS (Diluted)	-0.95	-1.32	-2.08	-2.32	-1.89	-2.08
EPS Growth	-62%	-37%	-10%	23%	-9%	14%
Free Cash Flow	-158	-200	-239	-225	-206	-181
Free Cash Flow Per Share	-0.71	-1.02	-1.52	-1.57	-1.51	-1.5
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	-671.05%	0%
Profit Margin	0%	0%	0%	0%	-676.31%	0%
Free Cash Flow Margin	0%	0%	0%	0%	-542.1%	0%
EBITDA	-213	-244	-300	-321	-245	-251
EBITDA Margin	0%	0%	0%	0%	-644.73%	0%
D&A For EBITDA	12	13	14	14	10	7
EBIT	-225	-257	-314	-335	-255	-258
EBIT Margin	0%	0%	0%	0%	-671.05%	0%
Effective Tax Rate	--	0%	--	--	0%	0%

Allogene Therapeutics Inc (ALLO) Price